NTHI Neonc Technologies Holdings, Inc.

Mentions (14)

• Newsglobenewswire.com·7d ago·Negative

  Powerful NeOnc Brain Cancer Pipeline Advances NeOnc (NASDAQ: NTHI) is scheduled to meet with the FDA for an in-person End-of-Phase 1 Type B meeting covering its experimental brain-cancer drug NEO212.

  View source ↗
• Newsglobenewswire.com·11d ago·Neutral

  NeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst DENVER, Sept. 24, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com ) -- NeOnc Technologies Holdings (NASDAQ: NTHI) has picked up fresh Wall Street coverage at a pivotal moment for its experimental brain-cancer pipeline.

  View source ↗
• Newsglobenewswire.com·15d ago·Neutral

  NeOnc Charting New Nasal Route to Treating Brain Cancer DENVER, Sept. 21, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – NeOnc Technologies Holdings' (NASDAQ: NTHI) NEO100 deserves attention; not just because its Phase 2a study has suddenly solved brain cancer, but because it is testing a different answer to one of the field's oldest problems.

  View source ↗
• Newsglobenewswire.com·20d ago·Positive

  NeOnc's $629K Insider Buying Spree Follows Breakthrough Data and Now All Eyes Turn to the FDA DENVER, Sept. 16, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com ) -- NeOnc Technologies Holdings (NASDAQ: NTHI) executives put even more personal capital behind the company, following positive Phase 2a results for its experimental brain-cancer therapy NEO100.

  View source ↗
• Newsglobenewswire.com·22d ago·Positive

  Insiders Continue Buying, as NeOnc Moves NEO100 Toward Its Next Regulatory Test DENVER, Sept. 14, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ: NTHI) is sending investors a signal that is impossible to ignore.

  View source ↗
• Newsglobenewswire.com·28d ago·Negative

  NeOnc' Phase 2 Data Could Put Cancer on the Ropes DENVER, Sept. 08, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – For NeOnc Technologies Holdings (NASDAQ: NTHI), the Phase 2a question has been answered.

  View source ↗
• Newsglobenewswire.com·38d ago·Neutral

  NeOnc's Phase 2A Success Could Set the Stage for Something Much Bigger DENVER, Aug. 28, 2026 (GLOBE NEWSWIRE) -- For NeOnc Technologies Holdings (NASDAQ: NTHI), the most important part of the NEO100 story may no longer be whether the company can produce a meaningful signal in recurrent brain cancer. After its latest Phase 2a readout, the bigger move is whether those results can support a credible path toward registration.

  View source ↗
• Newsglobenewswire.com·40d ago·Positive

  NeOnc's Clinical Story Is Now the Main Event DENVER, Aug. 26, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings (NASDAQ: NTHI) has reached a point where the market conversation can move toward a much more consequential question: What happens if NEO100's clinical results translate into a viable regulatory pathway for a difficult-to-treat form of brain cancer? On August 12, NeOnc reported positive topline Phase 2a results from its NEO100-01 study in patients with recurrent or progressive Grade …

  View source ↗
• Newsglobenewswire.com·48d ago·Positive

  NeOnc Technologies- Talk Is Cheap, Insider Buying Isn't DENVER, Aug. 18, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ: NTHI) has just added another potentially important element to an already potent story: its CEO, Amir Heshmatpour, is continuing to buy shares on the open market. According to the Form 4 transaction information provided by the company's latest filing, Heshmatpour purchased 12,000 NTHI shares on August 14 at an average price of $3.7883 and an…

  View source ↗
• Newsglobenewswire.com·50d ago·Neutral

  NTHI's Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results NeOnc's (NASDAQ:NTHI) Phase 2a results for NEO100 in recurrent IDH1-mutant high-grade glioma make its Nasdaq Global Market listing way more interesting

  View source ↗
• Newsnewsfilecorp.com·53d ago·Neutral

  Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) 2Q26 Dallas, Texas--(Newsfile Corp. - August 13, 2026) - NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI).

  View source ↗
• Newsglobenewswire.com·53d ago·Negative

  The Nose Knows: Why NeOnc's Patent Portfolio Could Make NTHI More Than a One-Drug Biotech DENVER, Aug. 13, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings' (NASDAQ: NTHI) August 12 headline was impossible to miss, but another interesting solution may be hiding in plain sight: while NeOnc produced encouraging data for one cancer drug, it also generated human clinical evidence around a non-invasive intranasal delivery strategy designed to reach the brain without relying on conventional system…

  View source ↗
• Newsglobenewswire.com·54d ago·Neutral

  Targeting The Mutant: NTHI's NEO100 Data Could Open a New Front in the Fight Against Brain Cancer DALLAS, Aug. 12, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings (NASDAQ: NTHI) has delivered the kind of clinical update that can change the conversation around a small biotechnology company: its Phase 2a study of intranasal NEO100 in recurrent IDH1-mutant high-grade glioma met its primary endpoint, with six-month progression-free survival of 48.9% versus a pre-specified 20% benchmark for stan

  View source ↗
• Newsnewsfilecorp.com·56d ago·Positive

  NTHI Brain Cancer Phase 2 Data Expected to Spark Triple Confluence Houston, Texas--(Newsfile Corp. - August 11, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) is set up for a potential high impact catalyst day with what market observers are describing as a classic triple confluence setup. The company will release topline Phase 2a results for its intranasal NEO100 therapy in recurrent IDH1-mutant high-grade glioma, a difficult-to-treat form of brain cancer on Wednesday, August 12 at 8:30 a.m.

  View source ↗